Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
Exelixis
Exelixis is a small Molecules founded in 1994.
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Company
Organization
AngelList URL
angel.co/exelixis-1
B2X
B2B
0
Board of Directors
George Poste
0
Jack Wyszomierski
0
Michael M. Morrissey
0
Stelios Papadopoulos
0
Maria C. Freire
0
Carl B. Feldbaum
0
CAGE Code
4GP15
0
CEO
Michael M. Morrissey
0
CIK Number
939,767
0
Legal Name
Exelixis, Inc.
Company Operating Status
Active
Contact Page URL
exelixis.com/contact-us/
Country
United States
Crunchbase URL
crunchbase.com/organiz...exelixis
DUNS Number
879810109
0
Facebook URL
@exelixisinc
Fax Number
(650) 837-8300
Founded Date
1994
0
Full Address
1851 Harbor Bay Parkway Alameda, CA 94502, USA
Headquarters
South San Francisco, California
Industry
Oncology
0
Healthcare
Biomedical engineering
Pharmaceutical industry
Technology
Biology
Biotechnology
Engineering
Synthetic chemistry
IRS Number
43,257,395
0
Legal Entity Identifier
254900PJQB59O2O95R37
0
LinkedIn URL
@company/8013
Location
San Francisco
San Diego
United States
Alameda, California
South San Francisco, California
Number of Employees (Ranges)
1,001 – 5,000
0
Patents Assigned (Count)
107
Phone Number
+16508377000
Pitchbook URL
pitchbook.com/profiles.../41439-88
Place of Incorporation
Delaware
0
Previous Name
EXELIXIS INC
0
SIC Code
8,731
2,836
0
Exchange
Nasdaq
0
Stock Symbol
EXEL
0
Ticker Symbol
EXEL
Twitter URL
@exelixisinc
Official Website
exelixis.com
Wellfound ID
exelixis-1
Wikidata ID
Q5419989
Find more companies like Exelixis
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
SUBSCRIBE